Free Trial
NASDAQ:PRE

Prenetics Global 11/27/2024 Earnings Report

Prenetics Global logo
$21.10 +0.92 (+4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$20.98 -0.12 (-0.57%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prenetics Global EPS Results

Actual EPS
-$0.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Prenetics Global Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prenetics Global Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Prenetics Global Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Prenetics Global Limited Class A
See More Prenetics Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prenetics Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prenetics Global and other key companies, straight to your email.

About Prenetics Global

Prenetics Global (NASDAQ:PRE) (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America. Its consumer brand, CircleDNA, offers a direct-to-consumer genetic testing kit that reports on wellness traits, nutrition, fitness and inherited disease risks. On the corporate side, the company partners with healthcare providers, sports organizations and governments to deploy large-scale testing programs and personalized health initiatives. Prenetics also supports telehealth services, enabling remote consultations based on genetic and diagnostic results.

Founded in 2014 and headquartered in Hong Kong, Prenetics was established by CEO Danny Yeung, a tech entrepreneur with a background in fintech and digital platforms. Under his leadership, the company has expanded through strategic partnerships and investments in laboratory automation and data analytics. Prenetics completed a public listing on the Nasdaq in 2022, positioning itself to accelerate global market expansion and further develop its precision health offerings.

View Prenetics Global Profile